Stereotactic single-dose
radiotherapy (radiosurgery) of early stage nonsmall-cell lung
cancer (NSCLC)
Holger Hof,
Cancer 2007;110:148
The
clinical results after stereotactic single-dose radiotherapy of
nonsmall-cell lung cancer (NSCLC) stages I and II were evaluated.
Forty-two patients with biopsy-proven NSCLC received stereotactic
radiotherapy. Patients were treated in a stereotactic body frame and
breathing motion was reduced by abdominal compression. The
single
doses used ranged between 19 and 30 Gy/isocenter.
After a median follow-up period of 15 months the actuarial overall
survival rates and disease-free survival rates were 74.5%, 65.4%,
37.4%, and 70.2%, 49.1%, 49.1% at 12, 24, and 36 months after
therapy, respectively. The
actuarial local tumor control rates were 89.5%, 67.9%, and 67.9% at
12, 24, and 36 months after therapy, respectively. A
significant difference (P = .032) in local tumor control was found
for patients receiving 26-30 Gy (n = 32) compared with doses of less
than 26 Gy (n = 10). The effect of the tumor volume on local tumor
control was also evaluated. Although the difference was not
statistically significant (P = .078), the subgroup of tumors with a
tumor volume of less than 12 cm3 (n = 10) experienced no
tumor recurrence. Thirteen (31%) patients developed metastases
during follow-up, whereas isolated regional lymph node recurrence
was only encountered in 2 patients. No clinically significant
treatment-associated side effects were documented.
Stereotactic single-dose
radiotherapy is a safe and effective treatment option for patients
with early stage NSCLC not suitable for surgery. Especially for
small tumor volumes it seems to be equally effective as
hypofractionated radiotherapy, while minimizing the overall
treatment time. |
Treatment plans were designed using
at least 6 different coplanar or non-coplanar isocentric beam
directions, the maximum beam number was 8. Beam shaping was achieved
by the use of an integrated multileaf-collimator (leaf width at
isocenter 1 cm). In order to reduce the secondary build-up effect in
the tumor a photon energy of as low as 6 MeV was chosen. Plan
evaluation was performed based on dose-volume-histograms (DVH). The
dose-values to be met are displayed in Table. The total dose was
prescribed to the isocenter, with the 80%-isodose surrounding the
PTV.
|
Dose
Limits for Different Organs at Risk |
|
Organ |
Dose limit |
|
Lung (ipsilateral) |
V9Gy <20% |
Esophagus |
14 Gy/small volume |
Trachea |
14 Gy/small volume |
Heart |
7 Gy/small volume |
Spinal cord |
8 Gy/small volume |
|
With a delay of 2 to 4 days after
treatment planning the actual treatment was performed, applying a
single fraction. For verification of the patient position, an
additional CT scan of the tumor region was performed, with
deviations of bony landmarks exceeding 2 mm or tumor positions
outside the previously measured range of mobility being corrected by
patient repositioning. After successful completion the patient was
immediately brought to the treatment room in identical position.
Target point setup was accomplished by using stereotactic
coordinates. An additional position verification was performed at
the linear accelerator (LINAC) by orthogonal portal images being
compared with digitally reconstructed radiographs (DRR) of the
planning CT. Treatment was performed using a Siemens Mevatron LINAC
(Siemens, Concord, Erlangen, Germany) with a dose rate of 200 MU/minute
and an integrated motorized multileaf-collimator. The total dose
applied ranged from 19 to 30 Gy to the isocenter, which equals about
15.2 to 24 Gy to the PTV-surrounding 80%-isodose. In the following,
doses refer to the isocenter, if not otherwise mentioned. One
patient received 19 Gy, 2 patients 22 Gy, 7 patients 24 Gy, 14
patients 26 Gy, 10 patients 28 Gy, and 8 patients 30 Gy.For
determination of the influence of the radiation dose on local tumor
control, patients receiving doses of less than 26 Gy (n = 10) were
compared with patients receiving 26 to 30 Gy (n = 32). In the
log-rank test a statistically significant difference (P = .032) was
seen. Patients receiving
less than 26 Gy had an actuarial local tumor control rate of 62.5%
at 12 months and of 50% at 24 months and longer. Patients receiving
26 Gy or more had a local tumor control rate of 100% at 12 months
and of 72% at 24 months and longer
Only few data on the outcome after
stereotactic single-dose radiotherapy of early stage lung tumors
have been published so far. Wulf reported on the results of
stereotactic radiotherapy of 92 lung lesions (metastases and primary
lung cancers), of which 31 were treated with single doses of 26 Gy
prescribed to the 80%-isodose in a similar setup as our patients.
Remarkably, no tumor recurrence was noticed after a median follow-up
of 14 months. Hara reported on 59 malignant lung tumors
treated with single-dose radiotherapy, although only 11 of the
tumors included were primary lung tumors. Whereas the 1-year and
2-year local progression-free rates (LPFRs) were 93% and 78%,
respectively, they found an
LPFR at 2 years of only 52% in patients treated with 20 or 25 Gy
total dose, whereas the LPFR in patients receiving 30 Gy or more was
83%. This indicates a dose dependency even for high single
doses. Our data support that finding, showing significantly higher
local tumor control rates in the group receiving 26-30 Gy compared
with patients receiving less than 26 Gy. Normalizing the doses we
applied to the PTV-surrounding 80%-isodose resulted in significantly
lower radiation doses, ranging from 15.2 to 24 Gy, which could be
responsible for the somewhat inferior local control rates compared
with the publications mentioned above. Also, the pencil beam
algorithm used for dose calculation could overestimate the dose to
some extent. The effectiveness of dose escalation is also
demonstrated for hypofractionated radiation schemes. In a
retrospective analysis, Onishi evaluated 245 patients from 13
centers with early stage lung tumors treated with a wide variety of
doses per fraction (ranging from 3-12 Gy) and fraction numbers
(ranging from 1-25). For comparison of the dose effect they
calculated a BED based on a linear-quadratic model. As a result a
significant difference in
local disease recurrence was found for tumors receiving less vs more
than a BED of 100 Gy (26.4% vs 8.1%). Also, Wulf
concluded that there is a steep increase in tumor control
probability for radiation doses above a BED of 94 Gy at the
isocenter. A similar result is seen when transforming the single
doses we used to BED. Whereas the group with doses ranging from 26
to 30 Gy had a BED at the isocenter of close to 100 Gy up to 120 Gy,
the group receiving less than 26 Gy had a BED at the isocenter of
only 81.6 Gy or less. This confirms the impact of the 100 Gy BED on
local tumor control. In a phase 1 study by McGarry 47 patients
with stage Ia or Ib lung carcinomas received stereotactic
radiotherapy in 3 fractions, starting with a dose of 8 Gy per
fraction up to a dose of 24 Gy per fraction in stage Ib tumors. Only
1 failure occurred in the group receiving 16 Gy or higher doses,
whereas 9 local failures were seen in the group receiving less than
16 Gy per fraction.
To what extent the tumor volume has
an influence on local tumor control remains unclear. Whereas in the
data we present tumors smaller than 12 cm3 show a better
outcome than bigger tumors, these results are not statistically
significant and can only give a hint as to the importance of the
tumor volume. A reason for the statistically insignificant
comparison between T1 and T2 tumors could be that some tumors of the
T1 group exceeded the size of 12 cm3. Wulf treated
20 patients with stage I-II NSCLC using a hypofractionated treatment
approach consisting of 3 fractions of 10-12.5 Gy each (only 1
patient received a single-dose treatment of 26 Gy). Although these
patients had relatively large tumors, with a median CTV of 80 cm3
and a range of 5 to 277 cm3, actuarial local tumor
control rates of 92% 12 months and longer after treatment could be
achieved (median follow-up, 11 months). This could imply that
hypofractionated radiotherapy is superior to single-dose therapy in
large tumor volumes, where the effects of fractionation like
reoxygenation and redistribution gain importance. Nevertheless, the
patient numbers are much too small to date to provide sufficient
reliability on this issue. For smaller tumor volumes of less than 12
cm3 our data show comparably high tumor control rates, as
was shown for tumors treated with hypofractionation.
The influence of dose escalation on
the overall survival after radiotherapy of early stage lung cancer
was also shown in a retrospective analysis of 156 patients treated
with conventional radiotherapy, indicating the achievement of local
control and high radiation doses to be significant prognostic
factors Nagata treated 45 patients with stage I lung cancer
with a total dose of 48 Gy in 4 fractions. Besides a high local
tumor control rate of 98% after a median follow-up of 30 months,
disease-free and overall survival rates for stage Ia tumors after 1
and 3 years were as high as 80% and 72%, and 92% and 83%,
respectively. Even for stage Ib tumors the disease-free and overall
survival rates were relatively high, with 92% and 71%, and 82% and
72%, respectively. Compared with a surgical series that achieved
survival rates of more than 50% after 5 years, these data seem to be
at least comparable. Contrary to expectations, our data cannot
validate these results, showing much lower survival rates. However,
from our point of view the reason is not the single-dose
fractionation scheme used or the applied total dose, which would
also have an impact on the local tumor control rates, but patient
selection. Presumably, the bad overall medical condition of the
patients before treatment, as only patients not amenable to surgery
were treated, plays an important role in the survival outcome. This
deduction is supported by the long-term results of DFS, which were
superior to overall survival. Another reason could be a possible
initial underestimation of the tumor stage, as discussed below,
although the fact that the subgroup of patients not experiencing
metastatic disease had no better survival than the rest of the group
reduces this suggestion.
The use of very high radiation doses
always comprises the risk of inducing normal tissue toxicities. That
the occurrence of clinically relevant toxicities is not induced by
high doses alone but is also influenced by the extent of the treated
volume is shown by McGarry Whereas no significant toxicities
were seen in patients with T1 tumors, dose-limiting toxicities
grade
3 occurred in 3 of 5 patients, with T2 tumors larger than 5 cm
receiving 72 Gy total dose. In our treatment we were far below
target doses as large as these, so the absence of relevant
toxicities in our patient group is not surprising. The low rate of
adverse events is also documented in other publications: In the
patient group treated by Nagata no pulmonary complications CTC
grade 3 or higher were encountered; only 2 patients experienced CTC
grade 2 toxicities. In contrast to the low rate of clinically
symptomatic changes, a vast majority of patients was diagnosed with
localized perifocal normal tissue changes. These changes seem not to
be extensive enough to cause symptoms but the difficulty of
separating them from tumor remains. Takeda examined 22
pulmonary lesions treated with hypofractionated stereotactic
radiotherapy. Subsequent CT scans revealed the occurrence of
ground-glass opacities 3 to 4 months after therapy in 18% of cases.
These corresponded closely with the planning target volume but were
unevenly distributed. Afterward, these opacities either dissolved or
evolved into dense consolidations. These dense consolidations even
occurred in 73% of all cases after a follow-up of 3 to 8 months.
Contrary to the early changes, these densities did not dissolve but
persisted, even after some shrinking. Similar findings were seen in
our patient group, where 64.3% of all patients developed dense areas
in the treated region. As these densities can hardly be
differentiated from possible tumor rests, we performed no further
discrimination of the local tumor control between partial and
complete response. Clinically, patients did not show increased side
effects, so the use of single-dose radiotherapy is not prohibitive
from the standpoint of normal tissue tolerance. In fact, even
further dose escalation should be tolerable, as the data by McGarry
suggest that dose-limiting toxicities occur at much higher dose
levels.
The low rate of normal tissue
toxicities also justifies treatment under shallow breathing, using a
simple means for breathing reduction, like abdominal compression, as
we did. The extent to which patients will further benefit concerning
treatment sequelae is arguable, despite the fact that more
sophisticated treatment methods such as gating techniques or tumor
tracking will allow for further normal tissue sparing.
An important question in the local
treatment of lung tumors is the possible extent of microscopic
metastasis. Whereas conventional radiotherapy often includes
lymphatic drainage in the radiation field, stereotactic radiotherapy
must be restricted to the visible tumor region because of the high
radiation doses used. For early stage lung cancer data exist
suggesting that an elective nodal irradiation can be omitted, as
isolated regional tumor recurrence is relatively rare. Still,
conventional CT scans can underestimate the existence of regional or
distant metastases. There are reports that conclude that up to 25%
of patients undergoing surgery for clinical stage I tumors harbor
lymph node metastases at the time of treatment. A means of detecting
occult disease could be the positron emission tomography (PET) scan.
A study examining 91 patients with clinical stage I lung cancer by
PET scans led to a surprising upstaging of 22 patients (24%) to
stage IIIA or IIIB. In our patient cohort a relatively large number
experienced regional or distant metastases during follow-up. It
therefore can be assumed that some of these patients were already
initially underestimated concerning their tumor stage, as no PET
examination was performed regularly. The effect a consequent
exertion of fluorodeoxyglucose (FDG)-PET in patient selection has on
the incidence of metastases during follow-up is documented by
Zimmermann In a group of 30 patients treated with
hypofractionated stereotactic radiotherapy for stage I NSCLC, all
patients received an initial FDG-PET examination. During a median
follow-up period of 18 months, 5 patients (17%) developed distant
metastasis, only 2 of them in regional lymph nodes. Despite the
relatively high number of metastases in our patient group, only 2
developed isolated regional lymph node metastases, supporting the
opinion that an elective nodal irradiation can be omitted in early
stage NSCLC.
Stereotactic single-dose radiotherapy
for early stage lung tumors is an effective and safe treatment
option for patients not amenable to surgery. Especially for small
tumor volumes it seems to be comparably effective to
hypofractionated treatment regimes. To what extent this also applies
to bigger volumes is unclear. A significant influence of dose
escalation on tumor control probability was shown. Despite the high
single doses, no severe toxicities occurred, indicating that there
is room for further dose escalation. For a final decision, longer
follow-up on possible late toxicities in patients receiving very
high doses up to 30 Gy/Isocenter (24 Gy/80%-isodose) will be useful.
Concerning patient selection, adequate measures, eg, PET, should be
adopted to avoid treatment of patients with advanced disease. |